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Introduction
Rare diseases are life-threatening or chronically debilitating 
conditions affecting no more than 5 in 10,000 people in the 
european Union. Most of the people suffering from rare 
diseases are actually affected by less frequently occurring 
diseases affecting one in 100,000 people or fewer (5, 8, 20).
the medicines intended for treatment of rare diseases are 
called “orphans” because the pharmaceutical industry has 
little interest, under normal market condition, in developing 
and marketing products intended for only a small number of 
patients suffering from very rare conditions (1, 2, 3, 4, 5, 9, 
11). Almost 80% of the rare diseases have identified genetic 
origins and a lot of them are treated with biotechnology-
derived medicinal products.
Some conditions occur so infrequently that the cost of 
developing and bringing a medicinal product to the market, 
as well as the cost to society is questionable (6, 7). At the 
same time patients suffering from rare diseases should be 
entitled to the same quality of treatment as other patients and 
their medicines should be both available and affordable in the 
country, especially in the poor ones (8, 9).
Regulation (ec) no 141/2000 and commission Regulation 
(ec) no 847/2000 provide the legislative frame for orphan 
medicines and rare diseases setting up the community 
procedure for designation of orphan drugs and incentives to 
the sponsors on a community level (10, 11). Rare diseases 
are presented as one of the priorities in the current european 
Union Public health Program running till 2013 and in addition 
to the initiatives on the eU level, the member-states develop 
further regional programmes to ensure adequate access to 
pharmacotherapy (12, 14, 15, 17, 18, 19).
the commission recommends that Member States put 
in place strategies organized around national plans for rare 
diseases and orphan medicines, adequate mechanisms for 
definition, codification and inventory of rare diseases and 
production of good practice guidelines, fostering research on 
rare diseases, including cross-border cooperation, ensuring 
access to high-quality healthcare, in particular through 
identifying national and regional centres of expertise (5, 18, 
22). Some researches are pointing that there are differences in 
patients’ access to orphan medicines in member state countries 
due to variety of reasons and their clarification is necessary in 
achieving the regulation goals (13, 21, 23, 24, 26).
the aim of our study was to evaluate the access to orphan 
medicines in Bulgaria based on the analysis of the Positive 
Drug list (PDl) and the share of biotechnology-derived 
products reimbursed for rare diseases in Bulgaria.
Materials and Methods
A regulatory analysis of the main european and corresponding 
Bulgarian laws and health regulations related to rare 
REIMBURSED ORPHAN MEDICINES IN BULGARIA AND THE SHARE OF 
BIOTECHNOLOGY-DERIVED PRODUCTS
Assena Stoimenova¹, Manoela Manova¹, Alexandra Savova¹, Bistra Angelovska², Guenka Petrova¹
¹Medical University, Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics,
Sofia, Bulgaria
2Goce Delcev University, Shtip, Macedonia
correspondence to: Assena Stoimenova
e-mail: assena_stoimenova@mail.bg
ABSTRACT
Rare diseases are life-threatening or chronically debilitating conditions affecting no more than 5 in 10,000 people in the European 
Union. Most of the people suffering from rare diseases are actually affected by less frequently occurring diseases affecting one 
in 100,000 people or fewer. Almost 80% of the rare diseases have identified genetic origins and lots of them are treated with 
biotechnology-derived medicinal products. The aim of our study was to evaluate the access to orphan medicines in Bulgaria 
based on the analysis of the Positive Drug List (PDL) and the share of biotechnology-derived products reimbursed for rare 
diseases in Bulgaria. Only 21 out of 56 medicines with European orphan designation and European marketing authorisation 
are available and funded in Bulgaria. 29% of them are biotechnology-derived. Another 17 (out of 47) orphan medicines with 
European marketing authorisation and without prior orphan designations in the EU are reimbursed and 59% of them are 
biotechnology-derived. Thus approximately just 37% of the orphan medicines (both with and without prior orphan designation) 
are available and funded in Bulgaria. Evidently the centralised marketing authorisation is not supported by the national regulatory 
requirements for price setting and inclusion into the PDL, which are necessary for guaranteeing medicines availability on the 
national market. The regulators and payers still do not ensure balance between the needs of patients and resources allocation.
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TABLE 1
Bulgarian legislation concerning rare diseases/orphan drugs
Law/regulation/other Scope of the document Relation to rare diseases/orphan drugs
Health Act (6) Public health care •	Chapter 4 “Health protection of specific groups of the 
population”, section 2 “Reproductive health”, paragraph 127 
(2), p. 5 requires prenatal diagnostics and prevention of genetic 
diseases.
•	Chapter 4 “Health protection of specific groups of the 
population”, section 4 “Genetic health and genetic tests”, 
paragraph 137-144 requires treatment, prevention and diagnostics 
of genetic diseases, treatment of hereditary diseases 
Law on Medicinal 
Products in Human 
Medicine (7) 
Marketing authorisation of 
medicinal products, licensing of 
pharmaceutical manufacturers, 
wholesalers, retailers, clinical 
trials, advertising, classification, 
pharmacovigillance, state 
control over the market, pricing 
of medicinal products and 
reimbursement.
•	Chapter 3 “Marketing authorisation”, paragraph 25 (1): 
reference to Regulation (ec) 141/2000 regarding the criteria for 
orphan drug and paragraph 25 (2) which is reference to Regulation 
762/2004 with regard to marketing authorisation of orphan drugs. 
•	Chapter 3 “Marketing authorisation”, paragraph 27, regarding 
the proof of orphan drug designation required as submission 
documentation for marketing authorisation.
•	Chapter 12 “Pricing of medicinal products”, paragraph 
262, (4), p.4: orphan drugs are part of the “positive” list (the 
reimbursement list).
•	Definition of orphan drug is given. 
Ministry of Health 
Regulation No 34 as of 
25.11.2005 (23)
lays down the provisions 
for prescribing, dispatching 
the products for treatment of 
diseases which are excluded 
from the obligatory health 
insurance.
According to Regulation 34/2005, article 2, (1), p.4 the treatment 
of rare diseases is funded by the Ministry of health. obsolete as of 
01.01.2007. 
Ministry of Health 
Regulation on Positive 
Drug List (24)
lays down the provisions for 
inclusion of medicinal products 
into the Positive list.
Regulates the inclusion of drugs into the positive list, including the 
drugs for the treatment of rare diseases.
diseases and orphan medicines was performed (27-33). the 
regulatory publications were reviewed and analysed from the 
perspective of their role for ensuring an access to adequate 
pharmacotherapy.
We have applied a three-step methodology in order to assess 
the availability of orphan drugs in Bulgaria: (1) Review of the 
list of orphan medicines in europe (with european market 
authorisation and with or without prior orphan designation in 
Europe) for orphan medicines clarification (16); (2) Review 
of Bulgarian PDL and identification of orphan drugs included 
(19); (3) Crossing the medicines identified in step (2) with the 
list of orphan medicines in europe (with european market 
authorisation and with or without prior orphan designation in 
europe) to evaluate the level of orphan drug availability in 
Bulgaria. the methods of manufacturing for each reimbursed 
orphan medicine were checked in the Summary of Product 
characteristics and european public assessment reports (33).
Results and Discussion
Bulgarian legislation on orphan drugs and rare diseases
Patients suffering from rare diseases in Bulgaria are estimated 
to be 400 000-450 000 people (5). there are six disease 
management centres for diagnosis and treatment of rare 
diseases in Bulgaria. the national legislation on orphan drugs 
comprises of several laws and regulations as presented in Table 
1, each having its role for the establishment of the legislation 
frame of treatment of rare diseases in Bulgaria.
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Fig. 1. Reimbursed orphan medicines and share of biotechnology-derived 
products
the health Act (3) outlines the genetic examinations and 
prenatal tests which are aimed at limiting the incidence of 
rare diseases in the country. the law on Medicinal Products 
in human Medicine (4) refers to Regulation (ec) 141/2000 
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(23) and sets up the conditions for marketing authorisation of 
orphan medicines, their pricing and funding. no reference is 
made in Bulgarian legislation to commission Regulation (ec) 
no 847/2000 of 27.04.2000 laying down the provisions for 
implementation of the criteria for designation of a medicinal 
product as an orphan medicinal product. thus no regulatory 
assistance is provided to the potential sponsors as intended 
with the commission Regulation (ec) no 847/2000 (7), 
neither does a clear interpretation exist for Regulation (ec) no 
141/2000 requirements at a national level.
the orphan medicines are authorised through the 
centralised procedure but in order to make them affordable on 
a national level a price need to be registered and a procedure 
for funding need to be regulated. Both processes are controlled 
by the Ministry of health in Bulgaria.
once included in the PDl, the orphan medicines are 
funded either by the health insurance Fund or by the state 
budget for the diseases which are excluded from the scope of 
the obligatory health insurance.
Analysis of the orphan medicines included in the 
Bulgarian Positive Drug List
the Bulgarian Positive Drug list (19) consists of four annexes 
which are divided based on the sources of funding. For the 
purpose of this publication we studied the orphan medicines, 
which are included in Annexes 3 and 4 and are fully reimbursed 
by the state budget.
our analysis is separated in two parts- availability of 
orphan medicines with european marketing authorisation and 
prior orphan designation in europe, and availability of orphan 
medicines with european marketing authorisation and without 
prior orphan designation in europe into the Bulgarian PDl.
the orphan medicines with european marketing 
authorisation and prior orphan designation in europe that are 
included in the Bulgarian PDl are presented in Table 2. there 
are 21 orphan medicines identified (10 in Annex 3 and 11 in 
Annex 4), representing treatment for 6 anatomical systems, 
but mainly various types of leukaemia, renal cell carcinoma, 
mucopolysaccharidosis, acromegaly etc. it is necessary to 
clarify that the list with medicines also provides the list with 
specific diagnoses for which they are funded.
the orphan medicines with european marketing 
authorisation and without prior orphan designation in europe 
available in Bulgarian PDl are presented in Table 3. We have 
identified 17 orphan medicines (16 in Annex 3 and 1 in Annex 
4) representing treatment for diseases of 3 anatomical systems: 
haemophilia, thalassaemia, various types of cancer, juvenile 
idiopathic arthritis etc.
the relative shares of both studied groups of orphan 
medicines which are reimbursed in Bulgaria are presented in Fig. 
1. in comparison with all orphan medicines centrally placed on 
the market only 21 out of 56 with european orphan designation 
and european marketing authorisation are available and funded 
in Bulgaria. 29% of them are biotechnology-derived. Another 
17 (out of 47) orphan medicines with european marketing 
authorisation and without prior orphan designation in eU are 
reimbursed and 59% of them are biotechnology-derived. thus 
approximately 37% of the orphan medicines (both with and 
without prior orphan designation) are available and funded in 
Bulgaria.
Although there are a lot of initiatives regarding the rare 
diseases and orphan medicines at the national level it is evident 
that still the Bulgarian legislation is not fully harmonised 
with the corresponding european documents (33). there are 
chapters dealing with rare diseases in the health Act and with 
orphan medicines in the law on Medicinal Products but a 
lot of other elements are missing as are the cooperation with 
marketing authorisation holders and full harmonisation with 
the european regulatory policy. thus patients suffering from 
rare diseases are also underserved in Bulgaria (19, 25, 27).
the latter conclusion is supported by the limited availability 
of the orphan medicines in the Bulgarian PDl. the reasons for 
such a limited access could be explained with financial reasons 
or with the existing therapeutic practice (9, 12). Unfortunately 
we do not possess the patient registries for all rare diseases, 
as well as official information about all the patients using 
orphan medicines and we could not evaluate their usage and 
compare with other countries (27). this is a major limitation 
of our study. Further studies need to be done to clarify the real 
patient access in respect of the financial affordability of main 
and supporting therapy.
the fact that only 37% of all medicines with orphan 
designation are available in the list with reimbursed medicines 
is very negative and shows that a lot of efforts need to be 
made at the national level for ensuring better patient therapy. 
evidently the centralised marketing authorisation is not 
supported by the following national regulatory requirements 
for price setting and inclusion into the PDl, which are 
necessary for guaranteeing medicines availability on national 
market. thus we can conclude that the regulators and payers 
still did not ensure a balance between the needs of patients and 
resources allocation.
Conclusions
Although the commission recommends that Member States 
put in place strategies organized around national plans for 
rare diseases and orphan medicines, ensuring access to high-
quality healthcare, there are significant differences in orphan 
drug availability amongst the countries. the access to orphan 
medicines through the Bulgarian PDl is limited for patients 
with rare diseases and further studies about their affordability 
both for the reimbursement system and for the patients need 
to be done. the Bulgarian health legislation needs of further 
development to introduce important european requirements 
concerning the access to orphan medicines. the lack of 
national guidelines on treatment of rare diseases did not allow 
us to assess the availability of supportive treatment. We could 
recommend establishment of disease management national 
guidelines focused not only on orphan drugs but on patient and 
his/her disease including non-orphan treatment.
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